指南与共识外周动脉疾病

外周动脉疾病人群中处方者实施指南导向药物治疗的情况仍然不佳

Prescriber implementation of guideline-directed medical therapy remains poor in the peripheral artery disease population.
指南 / 共识 · J Vasc Surg · 2025-02-19

这项回顾性队列研究纳入2017至2022年在单一大型学术三级转诊中心接受血管实验室影像检查的3471例外周动脉疾病患者,以2016年美国心脏协会指南定义最佳药物治疗。结果显示最佳药物治疗现患率为45.3%,高强度最佳药物治疗现患率为23.6%;60天内新发最佳药物治疗为24.3%,新发高强度最佳药物治疗为11.2%。作者认为外周动脉疾病人群应成为提高高强度最佳药物治疗依从性的目标人群,以预防心血管疾病发病和死亡。

要点

  • 最佳药物治疗现患率45.3%,高强度最佳药物治疗现患率23.6%。
  • 60天内新发最佳药物治疗24.3%,新发高强度最佳药物治疗11.2%。
  • 女性患者新发高强度最佳药物治疗较少(比值比0.7,95%置信区间0.52-0.91)。

核心结论

  • 尽管动脉粥样硬化性心血管疾病的最佳药物治疗指南明确,但在本真实世界研究中,外周动脉疾病指南导向管理的依从性仍然较低,尤其是高强度最佳药物治疗。
  • 适当高强度最佳药物治疗处方的预测因素包括较低的踝肱指数和非女性性别。
  • 鉴于外周动脉疾病高患病率、照护者的异质性以及筛查的广泛可及性,该人群应成为提高高强度最佳药物治疗依从性的目标人群,以预防心血管疾病发病和死亡。

研究设计与样本

  • 本研究为回顾性队列研究,纳入2017年至2022年在单一大型学术三级转诊中心接受血管实验室影像检查的3471例外周动脉疾病患者。
  • 最佳药物治疗依据2016年美国心脏协会指南定义,以抗血小板药物和他汀类药物的有效处方表示依从性。
  • 高强度最佳药物治疗定义为抗血小板药物联合高强度他汀类药物的处方。
  • 评估最佳药物治疗/高强度最佳药物治疗的现患率和发生率(指数踝肱指数后60天内转为最佳药物治疗/高强度最佳药物治疗)。
  • 建立多变量模型评估最佳药物治疗和高强度最佳药物治疗现患率及发生率的预测因素。

主要发现

  • 指数血管实验室检查时最佳药物治疗现患率为45.3%,高强度最佳药物治疗现患率为23.6%。
  • 60天内新发最佳药物治疗为24.3%,新发高强度最佳药物治疗为11.2%。
  • 年龄、最小/最大踝肱指数、保险状态、吸烟状态和合并症与最佳药物治疗/高强度最佳药物治疗现患率相关。
  • 年龄、性别、最小/最大踝肱指数、吸烟状态和糖化血红蛋白与高强度最佳药物治疗发生率相关。
  • 多变量模型中,女性患者新发高强度最佳药物治疗较少(比值比0.7,95%置信区间0.52-0.91),较低的踝肱指数可预测高强度最佳药物治疗(比值比0.6,95%置信区间0.51-0.72)。

关键数值与推荐

  • 最佳药物治疗依据2016年美国心脏协会指南定义,以抗血小板药物和他汀类药物的有效处方表示依从性。
  • 高强度最佳药物治疗定义为抗血小板药物联合高强度他汀类药物的处方。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Peripheral artery disease (PAD) is one of the most prevalent forms of cardiovascular (CV) disease, with many progressing to CV morbidity/death. Adherence to guideline-directed optimal medical therapy (OMT) in PAD is vital. This study evaluated provider adherence to OMT patients with PAD. METHODS: This is a retrospective cohort study of 3471 patients with PAD who underwent vascular laboratory imaging between 2017 and 2022 at a single large, academic, tertiary referral center. OMT was defined by 2016 American Heart Association guidelines. Adherence to guidelines was denoted by active prescriptions for antiplatelet and statin. The presence of high-intensity OMT (HIOMT) was defined as prescriptions for an antiplatelet and high-intensity statin. Prevalence and incidence (change to OMT/HIOMT within 60 days of index ankle-brachial index [ABI]) were evaluated. Multivariable models were created evaluating predictors of OMT and HIOMT prevalence and incidence. RESULTS: The OMT prevalence was 45.3%, whereas the HIOMT prevalence was 23.6% at the time of index vascular laboratory. Incident OMT was 24.3%, whereas incident HIOMT was 11.2% within 60 days. Age, minimum/maximum ABI, insurance status, smoking status, and comorbidities were associated with prevalent OMT/HIOMT. Age, gender, minimum/maximum ABI, smoking status, and hemoglobin A1C were associated with incident HIOMT. In multivariable models, incident HIOMT was less common for female patients (odds ratio: 0.7; 95% confidence interval: 0.52-0.91), whereas lower ABIs were predictive of HIOMT (odds ratio: 0.6; 95% confidence interval: 0.51-0.72). CONCLUSIONS: Despite clear guidelines regarding OMT for patients with atherosclerotic CV disease, in this real-world study of guideline-directed management of PAD, adherence to OMT remains low, especially for HIOMT. Predictors of appropriate HIOMT prescription include lower ABI and non-female sex. Given the high prevalence of PAD, the heterogeneity of caregivers, and the widespread availability of screening, this population should be targeted for better adherence to HIOMT to prevent CV morbidity and death.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Minnick C, Stafford J, Stutsrim A, et al. Prescriber implementation of guideline-directed medical therapy remains poor in the peripheral artery disease population. J Vasc Surg. 2025. PMID: 39984144. doi:10.1016/j.jvs.2025.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。